Latest news and press releases about Citius Pharmaceuticals, Inc. (CTXR): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies.
Price
| Price | $0.56 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.21 |
| EV / EBITDA | 0.06 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -67.15% |
| Return on Invested Capital | -67.62% |
| Return on Assets | -32.53% |
| Gross Margin | 19.97% |
| Operating Margin | -863.92% |
| Net Margin | -651.27% |
Related companies: ADTX · APLM · ATHA · CRIS · DARE · FBLG · ICU
Explore sector: Healthcare · Biotechnology
More sections of CTXR: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks